| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11753301 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Feb, 2030
(5 years from now) | |
| US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
| US8496973 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Mar, 2031
(6 years from now) | |
| US8568793 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Dec, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687506 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Feb, 2030
(5 years from now) | |
| US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
Nithiodote is owned by Hope Pharms.
Nithiodote contains Sodium Nitrite; Sodium Thiosulfate.
Nithiodote has a total of 7 drug patents out of which 0 drug patents have expired.
Nithiodote was authorised for market use on 14 January, 2011.
Nithiodote is available in solution, solution;intravenous, intravenous dosage forms.
Nithiodote can be used as sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning, sodium thiosulfate injection is administered by intravenous injection, sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning, treatment of acute cyanide poisoning that is judged to be serious or life-threatening, treatment of acute cyanide poisoning that is judged to be life threatening.
The generics of Nithiodote are possible to be released after 24 December, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 January, 2011
Treatment: Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning; Sodium thiosulfate injection is administered by intravenous injection; Tr...
Dosage: SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS
NITHIODOTE family patents
